Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination With Standard of Care for Newly Diagnosed Adult Glioblastoma
This study is testing a special immunotherapy treatment called DOC1021 alongside standard brain cancer treatments to see if it helps adults with a newly diagnosed aggressive brain tumor live longer. Researchers want to find out if adding this experimental treatment is safe and more effective than standard care alone.
You may be able to join if you are 18 or older, have a suspected diagnosis of glioblastoma that can be treated with surgery, and are well enough for standard chemotherapy and radiation. Certain conditions, such as pregnancy, active infections, or tumors in specific brain areas, mean you cannot participate.
Depending on your group, you will either receive standard care alone or standard care combined with the experimental immunotherapy injections and blood collections. All participants will have regular clinic visits for check-ups, scans, blood tests, and to monitor overall quality of life.
The study is recruiting at 17 locations in the United States: California, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Tennessee and Texas. There are no sites in Canada, and the Gilbert, Arizona site is not currently recruiting. Your care team can help you find the closest participating site.
- 1Tests an experimental immunotherapy called DOC1021 combined with standard brain cancer care.
- 2Open to adults 18 and older with a newly diagnosed aggressive brain tumor suitable for surgery.
- 3Recruiting at 17 U.S. sites in 10 states; none in Canada.
Related videos
2Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.